Moderna, Inc. reported third-quarter 2026 revenue of $1.313 billion, up 29% from $1.016 billion a year earlier, and returned to quarterly profitability with net income of $162 million compared with a $200 million loss in the corresponding 2025 period. The biotechnology company also raised its full-year revenue-growth expectation to 15% to 25%, substantially above its previous forecast for growth of up to 10%.
The results strengthen a recovery narrative around a company that has spent several years trying to rebuild its business after the collapse of pandemic-era COVID vaccine demand. However, the composition of the latest growth shows that Moderna has not yet completed that transition. The increase was driven primarily by higher international COVID vaccine sales under long-term government partnerships, while newer respiratory products remain early in their launches and the company’s most closely watched oncology programme is still awaiting regulatory submission and approval.
The quarter therefore represents genuine financial improvement without establishing that Moderna has already become the diversified mRNA company management has been building toward. Nine-month net losses remain substantial, operating cash flow is negative and the company’s stronger liquidity position partly reflects billions of dollars raised through convertible debt rather than internally generated cash.
How much of Moderna’s 29% revenue growth still comes from COVID vaccines?
Moderna recorded $1.273 billion in net product sales during the third quarter, up 31% from $973 million a year earlier. Total quarterly revenue reached $1.313 billion after including $40 million from collaboration, licensing, grant, royalty and manufacturing-related sources.
The company attributed most of the product-sales increase to higher COVID vaccine deliveries in international markets, particularly through long-term strategic partnerships with governments. United States revenue was $780 million during the quarter, while international markets contributed $533 million. Moderna said United States product sales were broadly consistent with the corresponding 2025 period, leaving overseas COVID demand as the principal source of incremental growth.
That geographic shift matters because Moderna is trying to create more predictable vaccine economics after years of volatile seasonal demand. Government agreements in countries including the United Kingdom, Canada and Australia can provide greater visibility than relying entirely on commercial retail vaccination campaigns. A five-year manufacturing agreement signed in Mexico during September extends that strategy into another market.
International contracts may therefore stabilise part of Moderna’s respiratory business, but they do not eliminate concentration risk. The company finished 2025 with $1.944 billion of annual revenue, largely generated by COVID vaccines, compared with $6.848 billion as recently as 2023. The latest quarter demonstrates that COVID can still produce meaningful growth, but Moderna’s longer-term valuation increasingly assumes that the platform will produce revenue from multiple diseases.
Why does Moderna’s $162 million quarterly profit not yet mean sustained profitability?
The return to quarterly profit is meaningful because Moderna lost $200 million in the third quarter of 2025. Operating income improved to $130 million from a $260 million operating loss, while diluted earnings per share reached $0.38 compared with a $0.51 loss a year earlier.
Cost reductions contributed materially to the improvement. Research and development expenditure declined 27% to $583 million from $801 million, primarily because of lower clinical-development spending following completion or winding down of several late-stage infectious-disease studies and broader efficiency measures. Moderna has now reduced its expected 2026 research and development spending to approximately $2.7 billion from a previous estimate of $2.9 billion.
The full-year financial picture remains less comfortable. Moderna recorded a net loss of $1.963 billion during the first nine months of 2026 and used approximately $2.715 billion of cash in operating activities. The quarter was profitable, but the company has not demonstrated sustained annual profitability.
Management is therefore balancing two objectives that can conflict. Moderna needs to reduce spending sufficiently to protect liquidity while still funding expensive late-stage programmes in cancer, rare disease and infectious disease. Cutting unsuccessful or lower-priority programmes can improve capital efficiency, but excessive retrenchment could reduce the number of future commercial products capable of replacing COVID vaccine revenue.
Why is Moderna abandoning another norovirus cohort after the Phase 3 interim analysis?
One sign of tighter portfolio discipline is the company’s decision not to initiate another cohort of its experimental norovirus vaccine programme during the current season. The Phase 3 interim analysis did not meet the statistical criteria required for early success, and Moderna now plans to discuss the programme’s future with health authorities.
The result is not equivalent to a completed Phase 3 failure because the company has not disclosed that the study missed its final primary endpoint. However, the decision not to expand the programme suggests management is applying a higher threshold before committing additional capital to another seasonal study cycle.
Norovirus remains a potentially attractive vaccine target because the infection causes a substantial burden of acute gastroenteritis and lacks a widely used licensed vaccine. That commercial opportunity alone does not justify continued spending if the emerging efficacy evidence is insufficient.
The decision is therefore relevant to investors assessing Moderna’s cost reduction strategy. A company operating with a still-large development portfolio needs to distinguish promising programmes from projects that consume cash without generating a sufficiently strong probability of approval. The norovirus decision indicates that Moderna is willing to stop or pause expansion rather than automatically fund another trial cohort.
Can mFLUSIVA and Moderna’s combination vaccine reduce dependence on seasonal COVID demand?
Moderna entered the current respiratory season with a broader commercial portfolio than it had a year earlier. The U.S. Food and Drug Administration approved its seasonal influenza vaccine mFLUSIVA in August for adults aged 50 to 64 years and granted accelerated approval for adults aged 65 years and older.
Commercial contribution from mFLUSIVA was immaterial during the third quarter because the approval arrived after much of the annual influenza contracting cycle had already occurred. Moderna consequently described the 2026 to 2027 season as a limited United States launch rather than evidence of the vaccine’s full commercial potential.
The company also has a combined influenza and COVID vaccine approved in Canada as mCOFLU and in the European Union as mCOMBRIAX. As of the end of September, the combination product had not yet generated commercial sales, while regulatory reviews were continuing in markets including Japan, the United Kingdom and Australia.
The United States remains more uncertain. Moderna is awaiting additional FDA guidance before attempting to refile the combination vaccine, meaning investors should not assume that international authorisations will automatically translate into U.S. approval.
If combination vaccination gains traction, it could simplify administration by allowing eligible patients to receive protection against influenza and COVID through one product. The commercial test will be whether governments, pharmacies, physicians and consumers value that convenience sufficiently to create meaningful incremental demand rather than simply shifting revenue between Moderna products.
Why is the intismeran melanoma programme more important to Moderna’s valuation than the earnings beat?
Moderna’s personalised cancer therapy intismeran autogene remains the company’s most consequential pipeline asset. Developed with Merck & Co., the investigational mRNA therapy is designed individually using mutations identified from each patient’s tumour and is administered alongside Keytruda.
The Phase 3 INTerpath-001 study in completely resected high-risk melanoma reported a 42% relative reduction in recurrence or death with intismeran plus Keytruda compared with Keytruda alone. The trial also showed a 38% relative reduction in distant metastasis or death, providing confirmatory late-stage evidence after an earlier randomised Phase 2 programme.
Moderna and Merck & Co. are working toward regulatory submissions and preparing for a potential commercial launch if authorities approve the treatment. Moderna has indicated that it intends to keep the United States filing on track during 2026, with 2027 representing a potential commercialisation window subject to regulatory decisions.
The opportunity is considerably larger than the immediate economics of a quarterly vaccine beat because successful approval would validate Moderna’s mRNA platform in cancer rather than infectious disease. Intismeran is already being tested across nine Phase 2 and Phase 3 studies involving several tumour types and disease settings, including non-small cell lung cancer.
That broader development programme also creates substantial execution risk. A personalised therapy must be manufactured separately for individual patients, creating turnaround-time, sequencing, logistics, quality-control and reimbursement challenges that conventional off-the-shelf medicines do not face. Positive melanoma efficacy therefore solves only part of the commercial problem.
Is Moderna’s $8 billion cash position as strong as the headline suggests?
Moderna ended September with approximately $8.0 billion in cash, cash equivalents and investments, up from $6.9 billion at the end of June. Management now expects to finish 2026 with between $8.1 billion and $8.3 billion, substantially above its earlier forecast of $4.7 billion to $5.2 billion.
The improvement needs qualification because a large portion came from financing rather than operating performance. Moderna issued approximately $3 billion of convertible senior notes during September and received about $2.6 billion of net proceeds after fees and transactions designed to reduce potential dilution.
The company simultaneously used $2.715 billion of cash in operating activities during the first nine months of the year. Its cash position therefore provides a substantial runway, but the higher year-end balance should not be interpreted as evidence that operations suddenly generated several billion dollars of excess cash.
Moderna also paid $950 million during the third quarter under its settlement with Arbutus Biopharma Corporation and Genevant Sciences. Its balance sheet included approximately $2.958 billion of convertible notes at September 30, introducing interest expense and potential future dilution considerations even though capped-call transactions were structured to mitigate some dilution risk.
The financing gives Moderna more flexibility to fund oncology and other development programmes. The trade-off is that the company must eventually demonstrate that those investments create products capable of supporting the enlarged capital structure.
Why could propionic acidemia become Moderna’s next major proof point outside vaccines and oncology?
Moderna’s registrational study of mRNA-3927 in propionic acidemia has reached its target enrolment, with pivotal data expected during 2026. The programme provides another test of whether the mRNA platform can deliver clinically useful therapeutic proteins inside the body rather than simply instructing immune cells to respond to infectious disease or cancer antigens.
Propionic acidemia is a rare inherited metabolic disorder in which patients cannot adequately break down certain amino acids and other substrates, leading to accumulation of toxic metabolites and potentially severe metabolic crises. mRNA-3927 is designed to provide instructions for cells to produce the missing functional enzyme components required to improve the relevant metabolic pathway.
Moderna has partnered with Recordati on the programme, and collaboration revenue contributed to the increase in other revenue during the first nine months. The clinical readout will nevertheless matter far more than near-term partnership accounting because a positive registrational result could validate a new therapeutic modality for the company.
Management has deferred a decision on moving its methylmalonic acidemia candidate mRNA-3705 into pivotal development until the propionic acidemia data are available. The result will therefore influence capital allocation across more than one rare disease programme.
What does Moderna’s 5.3% share-price rise say about investor expectations?
Moderna shares closed at $254.19 on November 6, rising 5.27% during the session after trading as high as $267.50. The stock was up approximately 14.5% over five trading days and about 35% over the preceding month.
The longer-term revaluation has been far more dramatic, with the shares trading many multiples above their late-2025 lows. That rally has coincided with stronger intismeran evidence, additional respiratory approvals and improving confidence that Moderna may finally be developing commercial businesses outside its original pandemic franchise.
The latest earnings helped the narrative by demonstrating that vaccine revenue can still surprise positively and that management is reducing expenditure. However, the share price now embeds substantially higher expectations than it did a year ago, increasing sensitivity to oncology regulatory progress, rare disease data and any signs that respiratory diversification is failing to translate into meaningful sales.
The next scheduled company event is Moderna’s analyst day on November 12. Investors will be looking for clearer timelines around the intismeran filing and manufacturing strategy, rare disease data, respiratory portfolio economics and the company’s longer-term expense trajectory.
What must Moderna prove after a profitable quarter and sharply higher revenue guidance?
The third-quarter results show that Moderna’s commercial business is stronger than the company expected earlier in the year. International COVID vaccine demand supported 29% revenue growth, product sales increased 31%, research spending declined and quarterly operations returned to profitability.
They also show why the transition remains unfinished. New influenza products contributed little to the quarter, the flu and COVID combination vaccine has not yet begun generating meaningful commercial revenue, the norovirus programme has encountered a statistical setback, and the company still consumed $2.7 billion of operating cash through September.
That leaves intismeran at the centre of Moderna’s next phase. Regulatory approval in melanoma could create the company’s first major therapeutic franchise outside respiratory vaccination and materially change how investors value the mRNA platform. Failure to commercialise it efficiently would leave Moderna more dependent on seasonal vaccine economics for longer.
The strongest interpretation of the November 6 results is therefore not that Moderna has completed its post-pandemic recovery. It is that the company has bought itself more financial runway, improved respiratory execution and reached a point where several late-stage programmes can finally determine whether diversification becomes real.
The next twelve months should provide the evidence. A cancer vaccine filing, the propionic acidemia readout, additional respiratory approvals and the first fuller commercial test of mFLUSIVA could collectively show whether Moderna is becoming a multi-franchise pharmaceutical company or remains a COVID-led vaccine business with a valuable but still largely investigational pipeline.
